Fujifilm Holdings Corporation (富士フイルムホールディングス株式会社, Fuji-fuirumu Hōrudingusu kabushiki gaisha), trading as Fujifilm (富士フイルム, Fuji-fuirumu), or simply Fuji, is a Japanese multinational conglomerate headquartered in Tokyo, Japan, operating in the areas of photography, optics, office and medical electronics,[2][3][4] biotechnology,[5][6] and chemicals.

Fujifilm products include document solutions, medical imaging and diagnostics equipment, cosmetics, pharmaceutical drugs, regenerative medicine, stem cells, biologics manufacturing, magnetic tape data storage, optical films for flat-panel displays, optical devices, photocopiers, printers, digital cameras, color films, color paper, photofinishing and graphic arts equipment and materials.

During this period, Fuji Photo developed digital technologies for its photography, medical, and printing sectors.

[12] Like its rival Eastman Kodak which dominated in the US, Fuji Photo enjoyed a longtime near-monopoly on camera film in Japan.

[citation needed] In 1994 vice president Juntarō Suzuki announced that the company would halt paying sōkaiya, a type of protection racket bribe, to Yakuza.

[18][19][20] The deal was subsequently dropped after intervention by activist investors Carl Icahn and Darwin Deason.

[3] Amid the 2020 COVID-19 pandemic, one of Fujifilm Toyama Chemical drugs, i.e. favipiravir, an antiviral commercially named Avigan, is being considered as a possible treatment for the virus,[8][23] after having been approved by China, Russia, and Indonesia authorities by June 2020.